Skip to main content

Table 4 Number of adverse effects of CBZ treatment

From: The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients

  Total (n = 118) High (n = 37) Low (n = 81) P (High vs Low)
Grade 4 neutropenia 53 (45%) 24 (65%) 29 (36%) < 0.001*
Febrile neutropenia 30 (25%) 13 (35%) 17 (21%) 0.118
Grade 3 thrombocytopenia 9 (8%) 6 (16%) 3 (4%) 0.026*
Grade 3 nausea 17 (14%) 5 (14%) 12 (15%) 1
Grade 2 diarrhea 13 (11%) 4 (11%) 9 (11%) 1
Grade 2 malaise 19 (16%) 4 (11%) 16 (20%) 0.296
Pneumonia 5 (4%) 2 (5%) 3 (4%) 0.648
  1. *P < 0.05